MOMETASONE FUROATE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for mometasone furoate and what is the scope of patent protection?

Mometasone furoate is the generic ingredient in six branded drugs marketed by Merck Sharp Dohme, Anda Repository, Cosette, Fougera Pharms, Glenmark Generics, Taro, Intersect Ent Inc, Perrigo Israel, Perrigo New York, Torrent, Amneal Pharms, and Apotex Inc, and is included in twenty-seven NDAs. There are thirteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Mometasone furoate has forty-five patent family members in twelve countries.

There are thirty drug master file entries for mometasone furoate. Seventeen suppliers are listed for this compound.

Summary for MOMETASONE FUROATE

International Patents:	45
US Patents:	13
Tradenames:	6
Applicants:	12
NDAs:	27
Drug Master File Entries:	30
Suppliers / Packagers:	17
Bulk Api Vendors:	63
Clinical Trials:	103
Patent Applications:	5,818
Formulation / Manufacturing:	see details
Drug Prices:	Drug price trends for MOMETASONE FUROATE
Drug Sales Revenues:	Drug sales revenues for MOMETASONE FUROATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOMETASONE FUROATE
DailyMed Link:	MOMETASONE FUROATE at DailyMed

See drug prices for MOMETASONE FUROATE

Drug Sales Revenue Trends for MOMETASONE FUROATE

See drug sales revenues for MOMETASONE FUROATE

Recent Clinical Trials for MOMETASONE FUROATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Libbs Farmacêutica LTDA	Phase 4
Lyra Therapeutics	Phase 2
Jeffrey Glassberg	Phase 2

See all MOMETASONE FUROATE clinical trials

Pharmacology for MOMETASONE FUROATE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Medical Subject Heading (MeSH) Categories for MOMETASONE FUROATE

Anti-Allergic Agents
Anti-Inflammatory Agents
Dermatologic Agents

Paragraph IV (Patent) Challenges for MOMETASONE FUROATE

Tradename	Dosage	Ingredient	NDA	Submissiondate
NASONEX	SPRAY, METERED;NASAL	mometasone furoate	020762	2009-08-07
ELOCON	LOTION;TOPICAL	mometasone furoate	019796	2004-06-10
ELOCON	CREAM;TOPICAL	mometasone furoate	019625

US Patents and Regulatory Information for MOMETASONE FUROATE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms	MOMETASONE FUROATE	mometasone furoate	SPRAY, METERED;NASAL	207989-001	Apr 3, 2017	AB	RX	No	No	Start Trial	Start Trial				Start Trial
Cosette	MOMETASONE FUROATE	mometasone furoate	LOTION;TOPICAL	077678-001	Nov 21, 2007	AB	RX	No	No	Start Trial	Start Trial				Start Trial
Glenmark Generics	MOMETASONE FUROATE	mometasone furoate	LOTION;TOPICAL	090506-001	Aug 9, 2010	AB	RX	No	No	Start Trial	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for MOMETASONE FUROATE

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	ASMANEX TWISTHALER	mometasone furoate	POWDER;INHALATION	021067-002	Feb 1, 2008	Start Trial	Start Trial
Merck Sharp Dohme	ELOCON	mometasone furoate	LOTION;TOPICAL	019796-001	Mar 30, 1989	Start Trial	Start Trial
Merck Sharp Dohme	ASMANEX TWISTHALER	mometasone furoate	POWDER;INHALATION	021067-001	Mar 30, 2005	Start Trial	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for MOMETASONE FUROATE

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	2008537695	Start Trial
Canada	2732355	Start Trial
Japan	2006520786	Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for MOMETASONE FUROATE

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0112669	96C0002	Belgium	Start Trial	PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
0548114	SPC/GB97/064	United Kingdom	Start Trial	PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.